Nikhil Prasad Fact checked by:Thailand Medical News Team Jan 09, 2025 10 hours, 14 minutes ago
Medical News: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive type of cancer that affects the blood and bone marrow, originating from early T-cell progenitors. Despite advancements in medicine, the treatment of T-ALL remains a challenge, especially in cases where the cancer becomes resistant to conventional therapies. Recent research conducted at Banaras Hindu University-India has shed light on a natural compound that could offer hope to patients battling this disease.
Melittin From Honey Bee Venom Shows Promise Against T Cell Leukemia
Melittin, a peptide found in honeybee venom, has demonstrated powerful anticancer properties in laboratory studies. Researchers from the Centre for Genetic Disorders, Department of Pathology, and Institute of Agricultural Sciences at Banaras Hindu University joined forces to investigate melittin’s effects on T-ALL cells. This
Medical News report explores the findings of their comprehensive study and delves into how melittin works as a potential anti-cancer agent.
Key Findings of the Study
The research team focused on the impact of melittin on Jurkat cells, a type of T-ALL cell line. They conducted a series of experiments to determine how melittin influences cancer cell viability, apoptosis (programmed cell death), and other critical cellular processes. Their results revealed several promising outcomes:
-Cytotoxic Effects on Cancer Cells
Melittin demonstrated a significant ability to reduce the viability of Jurkat cells. Using the MTT assay, the researchers determined that the compound’s IC50 value (the concentration required to kill 50% of cells) was 1 µg/mL. This effect was dose-dependent, with higher concentrations of melittin leading to greater reductions in cell viability.
-Induction of Apoptosis
One of melittin’s primary mechanisms of action is inducing apoptosis in cancer cells. The study showed that melittin activated pro-apoptotic genes such as Bax while downregulating anti-apoptotic genes like Bcl-2. Flow cytometry and fluorescence microscopy revealed that melittin-treated cells exhibited hallmarks of apoptosis, including chromatin condensation, nuclear fragmentation, and membrane blebbing.
-Reactive Oxygen Species (ROS) Generation
Melittin treatment led to an increase in intracellular ROS levels in Jurkat cells. Excessive ROS disrupts cellular function and contributes to apoptosis, making it a key factor in melittin’s anticancer activity.
-Mitochondrial Disruption
The mitochondrial membrane potential of Jurkat cells was significantly reduced following treatment with melittin. This disruption is a critical step in the intrinsic pathway of apoptosis, highlighting melittin’s targeted action on cancer cells.
-Cell Cycle Arrest
Melittin also caused cell cycle arrest in the G2-M phase, halting the proliferation
of Jurkat cells. This effect was observed in a dose-dependent manner, with up to 30% of cells arrested at higher concentrations of melittin.
Potential Implications of the Findings
The ability of melittin to selectively target cancer cells while sparing normal cells makes it a promising candidate for therapeutic development. The study’s findings suggest that melittin could be used as a standalone treatment or in combination with existing therapies to enhance their efficacy. However, the researchers emphasize the need for further studies to optimize melittin’s dosage and delivery methods to minimize potential side effects, such as hemolysis (destruction of red blood cells) observed at higher concentrations.
Broader Context and Future Directions
Melittin’s anticancer properties are not limited to T-ALL. Previous studies have demonstrated its effectiveness against other types of cancer, including breast and gastric cancers. The current study adds to the growing body of evidence supporting melittin’s potential as a versatile anticancer agent. Ongoing research aims to develop nanotechnology-based delivery systems to enhance melittin’s stability and reduce its toxicity.
Conclusion
The study conducted by researchers at Banaras Hindu University provides valuable insights into melittin’s potential as a novel treatment for T-cell acute lymphoblastic leukemia. By inducing apoptosis, disrupting mitochondrial function, generating ROS, and arresting the cell cycle, melittin effectively targets cancer cells and halts their progression. While the findings are promising, further investigations are needed to translate these laboratory results into clinical applications. The researchers hope that their work will pave the way for innovative therapies that improve outcomes for patients with T-ALL and other cancers.
The study findings were published on a preprint server and are currently being peer reviewed.
https://www.researchsquare.com/article/rs-5657703/v1
For the latest Cancer News, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/news/phytochemical-found-in-olive-oil-shows-promise-against-melanoma
https://www.thailandmedical.news/news/garcinia-brasiliensis-leaf-extracts-show-promise-in-tumor-treatment
https://www.thailandmedical.news/news/citrus-peel-oils-as-potential-game-changers-in-brain-cancer-therapy
Share
Tweet
Share
